1. OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial. (23rd January 2014) Authors: Vanhoutte, F.P.; Mazur, M.; Namour, F.; van der Aa, A.; Wigerinck, P.; van 't Klooster, G.A.E. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0236 Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, is Supported by Its Active Metabolite. (23rd January 2014) Authors: Namour, F.; Galien, R.; Vanhoutte, F. P.; Wigerinck, P.; van 't Klooster, G. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗